Advertisement
Product › Details
CER-001 (Cerenis)
Next higher product group | cardiovascular drug_o | |
Status | 2016-03-08 development p2 existent | |
Organisation | Cerenis Therapeutics S.A. | |
Today | Abionyx Pharma S.A. (Euronext Paris: ABNX) | |
Group | Abionyx (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for CER-001 (Cerenis)
- [1] Cerenis Therapeutics S.A.. (1/24/19). "Press Release: 2018 Annual Results and Clinical Update". Toulouse & Lakeland, US....
- [2] Cerenis Therapeutics S.A.. (11/8/17). "Press Release: Cerenis Therapeutics Acquires Lypro Biosciences Expanding Its HDL Strategy into Immuno-oncology and Chemotherapeutic Drug Delivery". Toulouse & Lakeland, US....
- [3] Cerenis Therapeutics S.A.. (3/1/17). "Press Release: Cerenis Therapeutics Announces Top Line Results of CARAT Phase II Study. No Statistical Difference Observed between CER-001 and Placebo". Toulouse & Ann Arbor, MI....
- [4] Cerenis Therapeutics S.A.. (2/17/16). "Press Release: 2016 Annual Results. Solid Cash Position of €24.7 million and Finalization of CARAT Phase 2 Clinical Study". Toulouse & Ann Arbor, MI....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top